Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: Efanesoctocog Alfa in Haemophilia A
NCT06752850Phase 4Active, not recruiting
- Sponsor
- Sobi
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 4 trial of efanesoctocog alfa in hemophilia A, sponsored by Sobi. Started Dec 2024; status: active, not recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06752850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752850.